Bocxman,
I don't have any trouble reading. Have you read the latest press release? Contrary to what you keep dredging up, this press release is the latest information BioCurex investors have. I will give you verbatim what Dr. Moro publically stated:
"These results complement those previously announced for breast cancer and they strongly suggest that the RECAF blood test could detect early stages of all the major cancer types"
My comment: Did you happen to notice the hedge word "could" in the above sentence? Dr. Moro doesn't know for sure if the RECAF blood test can detect early stages of all the major cancer types.
"We have reported on the ability of RECAF to detect cancers of many tissue types using samples which grouped early and late stage cancers. The present study further differentiates the stage of the cancer in comparison to normal and benign prostatic growths."
My comment: Dr. Moro is stating that the data presented in the last press release differentiates (shows the difference) in the stage of the cancer compared to normal growth or benign (non cancerous) growths of the prostate gland. The data shows a sensitivity of only 75% for early stage (I and II) when comparing cancer patients with normal individuals. And the data also shows a sensitivity of only 68% for early stage (I and II) when comparing cancer patients with patients with benign (non cancerous) growths of the prostate gland.
Continuing on verbatim with what Dr. Moro stated. Please follow along word for word from the press release if you want to do that.
"So far, in all of our studies on different cancers, we have compared the average amount of RECAF in the blood of different groups of individuals (e.g. normal donors, patients with benign tumors, or cancer patients), but the normal amount of RECAF - or any other protein in blood - varies from one individual to another."
My comment: Just like you (Bocxman) have been saying, over and over, Dr Moro is telling us that before this study, BioCurex has been comparing the average amount of RECAF in the blood of different groups of people. But now he tells us that the amount of RECAF in the blood varies with different people.
Now, the next two sentences of the same paragraph. "Therefore, a range of values is used to determine if a person has cancer. This means that the RECAF value we use to determine if a person has cancer must necessarily be high in order to avoid informing a healthy individual that he has cancer, when he may just be at the upper end of the RECAF normal spectrum.
My comment: Dr. Moro is saying that because the amount of RECAF in the blood varies with different people, a range of values is used to determine if a person has cancer and the range of values must be set high in order to avoid informing a healthy individual that he has cancer when he does not.
On to the next two sentences of the same paragraph. "But if we did sequential blood tests on each person and assuming their RECAF value was rather constant over time, then a small change in the level of circulating RECAF would detect cancer at the earliest stages."
My comment: These sentences are saying that if several of the early detection serum (blood) RECAF cancer screening tests were given to one person over some period of time, that a baseline amount of RECAF in the blood might be established for a particular person. If a later test was given and the RECAF value was above the established baseline amount, then cancer might be detected at the earliest stages.
Now the next sentence. "We do not know yet if the normal RECAF concentration is constant enough to make this personalization possible."
My comment: BioCurex does not know if the amount of RECAF in the blood is consistent enough to establish a baseline amount of RECAF in the blood for a particular person.
The final two sentences read "However, if it was consistent, this suggested approach might prove to be a winning strategy in the fight against cancer. We could then have a exquisitely sensitive tool to detect many types of cancer."
My comment: The two sentences immediately above contain two hedge words. The first is "might" and the second is "could." Dr. Moro is essentially saying that he needs a more "sensitive tool" to detect many types of cancer in their earliest stages. He is saying that he needs to be able to lower the RECAF range of values BioCurex is using to detect cancer.
Bocxman,
You continually insult me. You have called me darling. You have called me childish. You have called me brilliant. You have told me to sell my 150 shares of BioCurex stock. How will you insult me this time for just commenting on what Dr. Moro has publically stated in a press release? I feel sorry for you. kag
